MAM
DYN icon

Martingale Asset Management’s Dyne Therapeutics DYN Stock Holding History

Martingale Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,654
Closed -$465K – 849
2026
Q1 		$465K Buy
25,654
+502
+2% +$8.66K 0.01% 657
2025
Q4 		$492K Sell
25,152
-1,898
-7% -$35.9K 0.01% 612
2025
Q3 		$342K Buy
+27,050
New +$309K 0.01% 673
2023
Q2 		– Sell
-10,441
Closed -$120K – 820
2023
Q1 		$120K Sell
10,441
-24,825
-70% -$322K ﹤0.01% 801
2022
Q4 		$409K Buy
+35,266
New +$408K 0.01% 659
2022
Q1 		– Sell
-31,814
Closed -$379K – 825
2021
Q4 		$379K Buy
+31,814
New +$447K ﹤0.01% 694

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Martingale Asset Management's DYN Position: Q2 2026 in Review

Martingale Asset Management sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 25,654 shares — an estimated $465K sold.

Martingale Asset Management first reported a position in DYN in Q4 2021 and held it in 6 quarters. The position peaked at $492K in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Martingale Asset Management reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Martingale Asset Management sold 25,654 Dyne Therapeutics shares in Q2 2026, an estimated $465K.
  • Martingale Asset Management first reported a position in Dyne Therapeutics in Q4 2021 and held it in 6 quarters.
  • Martingale Asset Management's Dyne Therapeutics position peaked at $492K in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.